Evidence grade: WEAK — Supported only by weak or preliminary evidence.
computed from the encoded evidence by the Atlas grading rule.
Meta-analyses support ACR TI-RADS; it reduces unnecessary FNA while maintaining malignancy detection
Interobserver variability in feature scoring persists, systems (ACR/ATA/K-TIRADS) disagree, and performance varies by population
Determines which nodules get biopsied; over-call drives unnecessary FNA, under-call misses cancer.
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.